Dystrophic Epidermolysis Bullosa Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen, Abeona Therapeutics

DelveInsight's "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dystrophic Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dystrophic Epidermolysis Bullosa Market Forecast
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Dystrophic Epidermolysis Bullosa Market Report:
• The Dystrophic Epidermolysis Bullosa market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, The FDA has granted approval to Abeona Therapeutics' prademagene zamikeracel (pz-cel; EB-101), an autologous gene-corrected epidermal sheet therapy, for treating patients with recessive dystrophic epidermolysis bullosa (RDEB). The therapy will be sold under the brand name Zevaskyn.
• In April 2025, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYNTM (pronounced 'ZEE-vah-skin') (prademagene zamikeracel), also known as pz-cel, as the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and debilitating genetic skin disorder. Currently, there is no cure for RDEB, and ZEVASKYN is the only FDA-approved treatment that addresses RDEB wounds with a single application.
• In February 2025, New data from a clinical trial reveal that CORDStrom, a stem cell therapy under development by Inmune Bio, effectively reduced itching and pain in children-from infants to teenagers-suffering from intermediate to severe recessive dystrophic epidermolysis bullosa (RDEB). The treatment also decreased disease activity and skin involvement in the participants, whose ages ranged from 6 months to 15 years.
• In February 2025, Castle Creek Biosciences has raised $75 million in funding to advance a Phase 3 trial of its gene therapy aimed at enhancing wound healing in patients with dystrophic epidermolysis bullosa (DEB). The royalty financing deal for Castle Creek's therapy, D-Fi, was led by Ligand Pharmaceuticals, which contributed $50 million. Ligand indicated that investors will receive a "high single-digit royalty" on global sales if the treatment reaches the market.
• In November 2024, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy being evaluated as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB).
• The total market size for Dystrophic Epidermolysis Bullosa in the 7MM was approximately USD 550 million in 2023, and it is anticipated to grow during the forecast period.
• In 2023, the United States held the largest market size among the 7MM, totaling approximately USD 400 million.
• Among the EU4 and the UK, the UK represented the largest market size for Dystrophic Epidermolysis Bullosa, amounting to approximately USD 50 million.
• Spain recorded the smallest market size for Dystrophic Epidermolysis Bullosa among the 7MM, totaling approximately USD 20 million.
• In the 7MM, the total number of diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in 2023 was around 6,500, with the highest number reported in the US at approximately 3,500 cases, representing about 50% of the total.
• The United States had the highest total number of prevalent cases of Dystrophic Epidermolysis Bullosa in the 7MM, totaling 3,500 cases.
• In 2023, the age group most affected by Dystrophic Epidermolysis Bullosa included individuals aged 1 to 9 years, with approximately 1,300 cases reported.
• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• The Dystrophic Epidermolysis Bullosa epidemiology based on type-specific cases analyzed that the number of cases of dominant dystrophic epidermolysis bullosa is slight higher than recessive dystrophic epidermolysis bullosa
• The Dystrophic Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dystrophic Epidermolysis Bullosa pipeline products will significantly revolutionize the Dystrophic Epidermolysis Bullosa market dynamics.

Dystrophic Epidermolysis Bullosa Overview
Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by fragile skin that is prone to blistering and wounding, often in response to minor friction or trauma. It results from mutations in the collagen genes, specifically COL7A1, leading to a deficiency or dysfunction of type VII collagen, which is essential for anchoring the layers of skin together. DEB can vary in severity, with symptoms ranging from mild skin fragility to severe complications, including scarring, deformities, and an increased risk of skin infections and skin cancer. Management focuses on wound care, pain relief, and preventing complications, as there is currently no cure for the condition.

Get a Free sample for the Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation:
The Dystrophic Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Dystrophic Epidermolysis Bullosa
• Prevalent Cases of Dystrophic Epidermolysis Bullosa by severity
• Gender-specific Prevalence of Dystrophic Epidermolysis Bullosa
• Diagnosed Cases of Episodic and Chronic Dystrophic Epidermolysis Bullosa

Download the report to understand which factors are driving Dystrophic Epidermolysis Bullosa epidemiology trends @ Dystrophic Epidermolysis Bullosa Epidemiology Forecast
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dystrophic Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Dystrophic Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dystrophic Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dystrophic Epidermolysis Bullosa Therapies and Key Companies
• VYJUVEK (beremagene geperpavec): Krystal Biotech
• FILSUVEZ (birch triterpenes): Chiesi
• PTW-002 10 mg/g gel: Phoenicis Therapeutics
• AGLE 102: Aegle Therapeutics
• ALLO-ASC-SHEET: Anterogen Co., Ltd.
• EB-101: Abeona Therapeutics, Inc
• FCX-007: Castle Creek Bioscience
• PTR-01: Phoenix Tissue Repair, Inc.
• SD-101-6.0 cream: Scioderm, Inc.
• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Discover more about therapies set to grab major Dystrophic Epidermolysis Bullosa market share @ Dystrophic Epidermolysis Bullosa Treatment Landscape
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dystrophic Epidermolysis Bullosa Market Strengths
• A rising number of clinical trials are underway to assess innovative treatment approaches that have the potential to alter the progression of dystrophic epidermolysis bullosa and relieve its symptoms.
• Gene therapies for dystrophic epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy

Dystrophic Epidermolysis Bullosa Market Opportunities
• Currently, the lack of a cure and approved treatment presents a significant commercial opportunity for companies active in developing regenerative medicines, that is, cell and gene therapies.
• Significant advancements have been achieved in comprehending the molecular genetics and underlying mechanisms of dystrophic epidermolysis bullosa, laying the groundwork for developing potential treatments.

Scope of the Dystrophic Epidermolysis Bullosa Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others
• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

To know more about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit @ Dystrophic Epidermolysis Bullosa Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dystrophic Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Dystrophic Epidermolysis Bullosa
3. SWOT analysis of Dystrophic Epidermolysis Bullosa
4. Dystrophic Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Dystrophic Epidermolysis Bullosa Market Overview at a Glance
6. Dystrophic Epidermolysis Bullosa Disease Background and Overview
7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Dystrophic Epidermolysis Bullosa
9. Dystrophic Epidermolysis Bullosa Current Treatment and Medical Practices
10. Dystrophic Epidermolysis Bullosa Unmet Needs
11. Dystrophic Epidermolysis Bullosa Emerging Therapies
12. Dystrophic Epidermolysis Bullosa Market Outlook
13. Country-Wise Dystrophic Epidermolysis Bullosa Market Analysis (2020-2034)
14. Dystrophic Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Dystrophic Epidermolysis Bullosa Market Drivers
16. Dystrophic Epidermolysis Bullosa Market Barriers
17. Dystrophic Epidermolysis Bullosa Appendix
18. Dystrophic Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Dystrophic Epidermolysis Bullosa Pipeline https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Dystrophic Epidermolysis Bullosa Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dystrophic Epidermolysis Bullosa market. A detailed picture of the Dystrophic Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Dystrophic Epidermolysis Bullosa treatment guidelines.

Latest Reports by DelveInsight:
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market
• Substance Use Disorder Market: https://www.delveinsight.com/report-store/substance-use-disorder-market
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.